Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189306
Status:
COMPLETED
Last Update Posted:
2010-08-10
First Post:
2005-09-13
Brief Title:
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5 Cream
Sponsor:
Graceway Pharmaceuticals LLC
Organization:
Graceway Pharmaceuticals LLC
Study Overview
Official Title:
An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5 Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label study to evaluate the safety and the ability of Imiquimod 5 cream applied topically to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up
Detailed Description:
Evaluate the long-term sustained clearance rate defined as the proportion of those subjects clinically clear of basal cell carcinoma BCC at the treated superficial BCC sBCC target tumor site at the 12-week posttreatment visit who remain clear during a 5 year follow-up period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None